Dian Diagnostics Group (300244.SZ): The size of accounts receivable matches the characteristics of the business model and the growth of revenue, mainly from medical institutions and government.
On June 12, Gelonhui reported that Dian Diagnostics Group (300244.SZ) stated on the investor interaction platform that the company attaches great importance to the efficiency of accounts receivable collection. The collection of accounts receivable is not only related to the performance and bonuses of employees, but we also established an organizational structure to manage accounts receivables, which decomposes from the group to the subsidiary to the business personnel, establishing a dynamic evaluation and monitoring system. Currently, the size of the company's accounts receivable is matched with the characteristics of the business model and the scale of revenue growth, mainly from medical institutions and the government.
Dian Diagnostics Group Co.,Ltd. (SZSE:300244) Is About To Go Ex-Dividend, And It Pays A 0.5% Yield
Dian Diagnostics Group Co.,Ltd. (SZSE:300244) is about to trade ex-dividend in the next three days. The ex-dividend date is one business day before a company's record date, which is the date on which
Dian Diagnostics Group (300244.SZ) plans to distribute 0.6 yuan per 10 shares, with the ex-rights and ex-dividends date on June 13th.
Dian Diagnostics Group (300244.SZ) announced that it plans to distribute annual equity dividends to all shareholders in 2023: 0.6 yuan (including tax) cash dividend per 10 shares. The ex-dividend and ex-right date is June 13, 2024.
Declining Stock and Decent Financials: Is The Market Wrong About Dian Diagnostics Group Co.,Ltd. (SZSE:300244)?
With its stock down 30% over the past three months, it is easy to disregard Dian Diagnostics GroupLtd (SZSE:300244). However, the company's fundamentals look pretty decent, and long-term financials
Dian Diagnosis (300244.SZ): We are working with partners to discuss the implementation of medical diagnostic applications in the field of HW Cloud and the Pangu Large Model
On May 24, Ge Longhui | Dian Diagnosis (300244.SZ) said on the investor interactive platform that the company is working with partners to discuss the implementation of medical diagnosis applications in the field of HW Cloud and the Pangu Big Model.
Dean Diagnosis (300244.SZ): Currently, there is no low-altitude economic layout
On May 24, Ge Longhui | Dian Diagnosis (300244.SZ) said on the investor interactive platform that the company currently does not have a low-altitude economic layout.
Dian Diagnosis (300244.SZ): Currently, the first overseas medical testing laboratory opened in Vietnam on April 19, 2024
On May 16, Ge Longhui | Dian Diagnosis (300244.SZ) said at the performance briefing that the company's first overseas medical testing laboratory has now opened in Vietnam on April 19, 2024. You can follow the company's regular reports on overseas business revenue.
These 4 Measures Indicate That Dian Diagnostics GroupLtd (SZSE:300244) Is Using Debt Reasonably Well
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that debt - which is usually involved in bankruptcies - is a very important factor, when
Dian Diagnosis (300244.SZ) has repurchased a total of 5,529,500 shares at a cost of 100 million yuan
Zhitong Finance App News, Dean Diagnosis (300244.SZ) announced that as of April 30, 2024, the company had repurchased 5,529,500 shares of the company's shares through a dedicated securities account, accounting for 0.88% of the company's current total share capital. The highest transaction price was 18.91 yuan/share, the minimum transaction price was 15.01 yuan/share, and the total transaction amount was RMB 100 million (excluding transaction fees).
Dean Diagnosis (300244.SZ): Net profit of 23.1705 million yuan in the first quarter decreased by 85.54% year on year
On April 26, Ge Longhui (300244.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 2,973 billion yuan, down 8.01% year on year; net profit attributable to shareholders of listed companies was 23.1705 million yuan, down 85.54% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 235.363 million yuan, down 83.01% year on year; basic earnings per share were 0.0371 yuan.
Earnings Miss: Dian Diagnostics Group Co.,Ltd. Missed EPS By 53% And Analysts Are Revising Their Forecasts
As you might know, Dian Diagnostics Group Co.,Ltd. (SZSE:300244) last week released its latest annual, and things did not turn out so great for shareholders. It wasn't a great result overall - wh
Dian Diagnosis (300244.SZ) announced its 2023 annual results, with net profit of 307 million yuan, a decrease of 78.56%
Zhitong Finance App News, Dean Diagnosis (300244.SZ) released its 2023 annual report. During the reporting period, the company achieved revenue of 13.408 billion yuan, a year-on-year decrease of 33.89%. Achieved net profit of 307 million yuan attributable to shareholders of listed companies, a year-on-year decrease of 78.56%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 295 million yuan, a year-on-year decrease of 81.90%. Basic earnings per share were $0.4918. It is proposed to distribute a cash dividend of 0.60 yuan (tax included) for every 10 shares to all shareholders. During the reporting period, the diagnostic service business was put into operation
Benign Growth For Dian Diagnostics Group Co.,Ltd. (SZSE:300244) Underpins Stock's 26% Plummet
Dian Diagnostics Group Co.,Ltd. (SZSE:300244) shareholders that were waiting for something to happen have been dealt a blow with a 26% share price drop in the last month. The recent drop completes
Be Wary Of Dian Diagnostics GroupLtd (SZSE:300244) And Its Returns On Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Ideally, a business will show two trends; firstly a growing return on capital employed (ROCE) an
Dian Diagnosis (300244.SZ) has repurchased 0.8% of its shares at a cost of 91.32 million yuan
Dean Diagnosis (300244.SZ) announced that as of March 29, 2024, the company had repurchased a total of 50 shares...
Dian Diagnostics GroupLtd (SZSE:300244) Adds CN¥362m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 41%
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But its virtually certain that sometimes you will buy stocks that fall
Dean Diagnosis (300244.SZ): Initial repurchase of 310,000 shares
On March 11, Ge Longhui (300244.SZ) announced that on March 8, 2024, the company repurchased 311,600 shares of the company's shares through a dedicated securities account through centralized bidding transactions, accounting for 0.05% of the company's current total share capital. The highest transaction price was 18.34 yuan/share, the lowest transaction price was 18.11 yuan/share, and the total transaction amount was RMB 5,686,962.
Both Individual Investors Who Control a Good Portion of Dian Diagnostics Group Co.,Ltd. (SZSE:300244) Along With Institutions Must Be Dismayed After Last Week's 4.3% Decrease
Key Insights Significant control over Dian Diagnostics GroupLtd by individual investors implies that the general public has more power to influence management and governance-related decisions The to
Benign Growth For Dian Diagnostics Group Co.,Ltd. (SZSE:300244) Underpins Stock's 27% Plummet
Dian Diagnostics Group Co.,Ltd. (SZSE:300244) shareholders that were waiting for something to happen have been dealt a blow with a 27% share price drop in the last month. The drop over the last 30
Dean Diagnosis (300244.SZ) pre-reduced. Net profit for 2023 is expected to be 300 million yuan to 400 million yuan, a year-on-year decrease of 72.11% to 79.08%
Dean Diagnosis (300244.SZ) disclosed the 2023 annual results forecast. The company is expected to be a shareholder of a listed company...
No Data